Creative Biolabs offers a comprehensive suite of laboratory testing solutions targeting BCL10 in a wide range of research areas. With our expertise, we work with clients to provide a unique approach to each project and optimal strategies from design to completion to support your biomarker discovery and validation.
Structural Organization of BCL10
BCL10 contains a CARD domain consisting of six tightly compressed alpha-helices and a C-terminal serine and threonine-rich functional domain. BCL10 protein covalently modifies phospholipid molecules on the plasma membrane through this domain, inducing phosphorylation, and recruiting card-related proteins to activate NF-κB.
Fig.1 BCL10 architecture and its regulatory mechanisms.1, 3
CARD11-BCL10-MALT1 Complexes
CARD-BCL10-MALT1 (CBM) is a multiprotein signaling platform that controls most tissue immune and inflammatory pathways. These CBM regulatory mechanisms are essential for host defense and tissue homeostasis, and many genetic changes in CBM signaling components are associated with inherited and acquired immune-mediated diseases.
Fig.2 Cell-type specific roles in CBM complex-mediated signaling pathways.2,3
Inborn errors in each component of CBM are associated with a group of primary immunodeficiency disorders which include combined immunodeficiency, selective B-cell lymphocytosis, and atopic diseases, etc. Until now, most of our knowledge of the mechanism has come from CBM complexes in lymphocytes. Thus, further exploration of the physiological and pathological functions of CBM signaling is expected to provide additional insights into the environment-specific functions of immune and inflammatory pathways in health and disease.
Services Provided by Creative Biolabs
The study of the mechanism of BCL10 will also enable us to further understand the role of CBM complex in disease. Our services can be customized to suit the specific needs of our clients, popular analysis services targeting BCL10 include but are not limited to the following:
- Antigen-Antibody Preparation:
| Cat | Service |
|---|---|
| BAS111-1 | BCL10 Antibody Development |
| BAS111-2 | BCL10 Protein Expression |
| BAS111-3 | BCL10 Mutants Expression |
| BAS111-4 | BCL10 Structure Analysis |
| BAS111-5 | BCL10 Function Analysis |
- Immunoassay:
| Cat | Service |
|---|---|
| BAS111-6 | BCL10 WB Assay |
| BAS111-7 | BCL10 Co-IP Assay |
| BAS111-8 | BCL10 IHC Assay |
| BAS111-9 | BCL10 IF Assay |
- Molecular Detection Analysis:
| Cat | Service |
|---|---|
| BAS111-10 | BCL10 PCR Assay |
| BAS111-11 | BCL10 Sequence Analysis |
| BAS111-12 | BCL10 Mutation Analysis |
Creative Biolabs is committed to providing the highest quality of custom services and products at the most reasonable prices. Please feel free to contact us for more information and a formal quote.
References
- Gehring, Torben, Thomas Seeholzer, and Daniel Krappmann. "BCL10–bridging CARDs to immune activation." Frontiers in immunology 9 (2018): 1539.
- McAuley, J. Randall, et al. "CARMA3 is a critical mediator of G protein-coupled receptor and receptor tyrosine kinase-driven solid tumor pathogenesis." Frontiers in Immunology 9 (2018): 1887.
- Distributed under CC BY-SA 4.0, without modification.
For Research Use Only.
